Cargando…

Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years

Vancomycin is an effective but potentially nephrotoxic antibiotic commonly used for severe infections. Dosing guidelines for vancomycin in obese children and adolescents with or without renal impairment are currently lacking. This study describes the pharmacokinetics of vancomycin in a large pediatr...

Descripción completa

Detalles Bibliográficos
Autores principales: Smit, Cornelis, Goulooze, Sebastiaan C., Brüggemann, Roger J. M., Sherwin, Catherine M., Knibbe, Catherijne A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038958/
https://www.ncbi.nlm.nih.gov/pubmed/33839974
http://dx.doi.org/10.1208/s12248-021-00577-x
_version_ 1783677494421880832
author Smit, Cornelis
Goulooze, Sebastiaan C.
Brüggemann, Roger J. M.
Sherwin, Catherine M.
Knibbe, Catherijne A. J.
author_facet Smit, Cornelis
Goulooze, Sebastiaan C.
Brüggemann, Roger J. M.
Sherwin, Catherine M.
Knibbe, Catherijne A. J.
author_sort Smit, Cornelis
collection PubMed
description Vancomycin is an effective but potentially nephrotoxic antibiotic commonly used for severe infections. Dosing guidelines for vancomycin in obese children and adolescents with or without renal impairment are currently lacking. This study describes the pharmacokinetics of vancomycin in a large pediatric cohort with varying degrees of obesity and renal function to design practical dosing guidelines for this population. A multi-center retrospective population pharmacokinetic study was conducted using data from patients aged 1−18 years who received >1 dose of vancomycin and had ≥1 vancomycin concentration measured between January 2006 and December 2012. Besides pharmacokinetic data, age, gender, body weight, creatinine clearance (CL(cr), bedside Schwartz equation), ward, race, and neutropenic status were collected. Population pharmacokinetic analysis and simulations were performed using NONMEM7.4. A total of 1892 patients (5524 samples) were included, with total body weight (TBW) ranging 6−188 kg (1344 normal weight, 247 overweight, and 301 obese patients) and CL(cr) down to 8.6 mL/min/1.73 m(2). The two-compartment model, with clearance (CL) significantly increasing with TBW and CL(cr), central and peripheral volume of distribution and inter-compartmental clearance increasing with TBW, performed well for all age, weight, and renal function ranges. A dosing guideline is proposed that integrates body weight and CL(cr) resulting in effective and safe exposures across all ages, body weight, and renal functions in the pediatric population. We have characterized the full pharmacokinetic profile of vancomycin in obese children and adolescents aged 1−18 years and propose a practical dosing guideline that integrates both body weight and renal function. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1208/s12248-021-00577-x.
format Online
Article
Text
id pubmed-8038958
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80389582021-04-27 Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years Smit, Cornelis Goulooze, Sebastiaan C. Brüggemann, Roger J. M. Sherwin, Catherine M. Knibbe, Catherijne A. J. AAPS J Research Article Vancomycin is an effective but potentially nephrotoxic antibiotic commonly used for severe infections. Dosing guidelines for vancomycin in obese children and adolescents with or without renal impairment are currently lacking. This study describes the pharmacokinetics of vancomycin in a large pediatric cohort with varying degrees of obesity and renal function to design practical dosing guidelines for this population. A multi-center retrospective population pharmacokinetic study was conducted using data from patients aged 1−18 years who received >1 dose of vancomycin and had ≥1 vancomycin concentration measured between January 2006 and December 2012. Besides pharmacokinetic data, age, gender, body weight, creatinine clearance (CL(cr), bedside Schwartz equation), ward, race, and neutropenic status were collected. Population pharmacokinetic analysis and simulations were performed using NONMEM7.4. A total of 1892 patients (5524 samples) were included, with total body weight (TBW) ranging 6−188 kg (1344 normal weight, 247 overweight, and 301 obese patients) and CL(cr) down to 8.6 mL/min/1.73 m(2). The two-compartment model, with clearance (CL) significantly increasing with TBW and CL(cr), central and peripheral volume of distribution and inter-compartmental clearance increasing with TBW, performed well for all age, weight, and renal function ranges. A dosing guideline is proposed that integrates body weight and CL(cr) resulting in effective and safe exposures across all ages, body weight, and renal functions in the pediatric population. We have characterized the full pharmacokinetic profile of vancomycin in obese children and adolescents aged 1−18 years and propose a practical dosing guideline that integrates both body weight and renal function. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1208/s12248-021-00577-x. Springer International Publishing 2021-04-11 /pmc/articles/PMC8038958/ /pubmed/33839974 http://dx.doi.org/10.1208/s12248-021-00577-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Smit, Cornelis
Goulooze, Sebastiaan C.
Brüggemann, Roger J. M.
Sherwin, Catherine M.
Knibbe, Catherijne A. J.
Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
title Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
title_full Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
title_fullStr Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
title_full_unstemmed Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
title_short Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
title_sort dosing recommendations for vancomycin in children and adolescents with varying levels of obesity and renal dysfunction: a population pharmacokinetic study in 1892 children aged 1–18 years
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038958/
https://www.ncbi.nlm.nih.gov/pubmed/33839974
http://dx.doi.org/10.1208/s12248-021-00577-x
work_keys_str_mv AT smitcornelis dosingrecommendationsforvancomycininchildrenandadolescentswithvaryinglevelsofobesityandrenaldysfunctionapopulationpharmacokineticstudyin1892childrenaged118years
AT gouloozesebastiaanc dosingrecommendationsforvancomycininchildrenandadolescentswithvaryinglevelsofobesityandrenaldysfunctionapopulationpharmacokineticstudyin1892childrenaged118years
AT bruggemannrogerjm dosingrecommendationsforvancomycininchildrenandadolescentswithvaryinglevelsofobesityandrenaldysfunctionapopulationpharmacokineticstudyin1892childrenaged118years
AT sherwincatherinem dosingrecommendationsforvancomycininchildrenandadolescentswithvaryinglevelsofobesityandrenaldysfunctionapopulationpharmacokineticstudyin1892childrenaged118years
AT knibbecatherijneaj dosingrecommendationsforvancomycininchildrenandadolescentswithvaryinglevelsofobesityandrenaldysfunctionapopulationpharmacokineticstudyin1892childrenaged118years